MAPK9 and neoplasm: In this context, miR-17, by inhibiting the mitogen-activated kinase JNK2, a cell cycle promoting protein [47], may have also a tumor suppressive role that has been demonstrated by evidence showing that loss of heterozygosity at 13q31.3 is associated with tumor progression and poor prognosis in several cancers [12, 53].